Biological targets for isatin and its analogues: Implications for therapy

Biologics: Targets and Therapy

Volumn 1, Issue 2, 2007, Pages 151-162

  Medvedev, Alexei ^a   Buneeva, Olga ^a   Glover, Vivette ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biological and pharmacological activity; Isatin; Isatin analogues; Isatin binding proteins; Isatin targets

Indexed keywords

EID: 57349102719     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Anand-Srivastava MB, Trachte GJ. 1993. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev, 45:455-97.
2. Benford HL, McGavan NW, Helfrich MH, et al. 2001. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone, 28:465-73.
3. Berry MD. 2004. Glyceradehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenera-tive disorders. J Psychiatry Neurosci, 29:337-45.
4. Bhattacharya SK, Chakrabati A, Sandler M, et al. 1996a. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity. Indian J Exp Biol, 34:1190-3.
5. Bhattacharya SK, Chakrabati A, Sandler M, et al. 1996b. Anxiolytic activity of intraventriculary administered atrial natriuretic peptide in the rat. Neuropsychopharmacology, 15:199-206.
6. Binda C, Li M, Hubalec F, Restelli N, et al. 2003. Insight into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA, 100:9750-5.
7. Buneeva OA, Gnedenko OV, Medvedeva MV, et al. 2006. Interaction of pyruvate kinase with isatin and deprenyl. Biomed Khim, 52:413-18.
8. Buneeva OA, Gnedenko OV, Panova NG, et al. 2003. Glycerol-3-phos-phate dehydrogenase - cytosolic isatin-binding protein. Biomed Khim, 49:627-31.
9. Buneeva OA, Medvedev AE. 2006. Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease. Biochemistry, 71:851-60.
10. Cane A, Tournaire MC, Barritault D, et al. 2000. The endogenous oxindoles 5-hydroxyoxindole and isatin are antiproliferative and proapoptotic. Biochem Biophys Res Commun, 276:379-84.
11. Carlile GW, Tatton WG, Borden KL. 1998. Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceradehyde-3-phosphate dehydrogenase. J Biochem, 335:691-6.
12. Cerchiaro G, da Costa Ferreira AM. 2006. Oxindoles and Copper Complexes with Oxindole-Derivatives as Potential Pharmacological Agents. J Braz Chem Soc, 17:1473-85.
13. Chambard J, Lefloch R, Pouysségur J, et al. 2007. ERK implication in cell cycle regulation. Biochimica et Biophysica Acta (2006) [Epub ahead of print] www.elsevier.com/locate/bbamcr
14. Chapman JG, Magee WP, Stukenbrok HA, et al. 2002. A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl) sulfonyl]isatin reduces myocardial ischemic injury. Eur J Pharmacol, 456:59-68.
15. Chen L-R, Wang Y-C, Lin YW, et al. 2005. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Let, 15:3058-62.
16. Chen SH, Tan SL. 2005. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem, 12:2317-42.
17. Chiyanzu I, Hansell E, Gut J, et al. 2003. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett, 13:3527-30.
18. Chohan ZH, Pervez H, Rauf A, et al. 2004. Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J Enzyme Inhib Med Chem, 19:417-23.
19. Chowdhury I, Tharakan B, Bhat GK. 2006. Current concepts in apoptosis: The physiological suicide program revisited. Cell Mol Biol Lett, 11:506-25.
20. Chiyanzu I, Hansell E, Gut J, et al. 2003. Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Let, 13:3527-30.
21. Cohen P. 1999. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond B Biol Sci, 354:485-95.
22. 3H]isatin in rat brain. J Neurochem, 84:618-20.
23. Dawson TM. 2006. Parkin and defective ubiquitination in Parkinson's disease. J Neural Transm Suppl, 70:209-13.
24. De Clerq E. 2001. Vaccinia virus Inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev, 14:382-97.
25. De Clerq E. 2005. Antiviral drug discovery and development: where chem- istry meets with biomedicine. Antiviral Res, 67:56-75.
26. De BP, Gupta S, Zhao H, et al. 1996. Specific interaction in vitro and in vivo of glyceraldehyde-3-phosphate dehydrogenase and LA protein with cis-acting RNAs of human parainfluenza virus type 3. J Biol Chem, 271:24728-35.
27. De Thonel A, Eriksson JE. 2005. Regulation of death receptors - relevance in cancer therapies. Toxicol Appl Pharmacol, 207(2 Suppl):123-32.
28. Diehl JA, Cheng M, Roussel MF, et al. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev, 12:3499-511.
29. Earnshaw WC, Martins LM, Kaufmann SH. 1999. Mammalian caspases: structure, activation, substrates and function during apoptosis. Ann Rev Biochem, 68:383-424.
30. Evguenieva-Hackenberg E, Schiltz E, Klug G. 2002. Dehydroge- nases from all three domains of life cleave RNA. J Biol Chem, 277:46145-50.
31. Gillam EMJ, Notley LM, Cai H, et al. 2000. Oxidation of indole by cyto- chrome P450 enzymes. Biochemistry, 39:13817-24.
32. Glover V, Bhattacharya SK, Chakrabarti A, et al. 1998. The pharmacology of isatin: A brief review. Stress Med, 14:225-9.
33. Glover V, Halket JM, Watkins PJ, et al. 1988. Isatin: identity with the puri- fied endogenous monoamine oxidase inhibitor tribulin. J Neurochem, 51:656-9.
34. Glover V, Medvedev A, Sandler M. 1995. Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors. Life Sci, 57:2073-9.
35. Guengerich FP, Sorrells JL, Schmitt S, et al. 2004. Generation of New Protein Kinase Inhibitors Utilizing Cytochrome P450 Mutant Enzymes for Indigoid Synthesis. J Med Chem, 47:3236-41.
36. Guttenplan N, Lee C, Frishman WH. 2001. Inhibition of myocardial apop- tosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition. Heart Dis, 3:313-28.
37. Hajra KM, Liu JR. 2004. Apoptosome dysfunction in human cancer. Apoptosis, 9:691-704.
38. Hinter AL, Choy JC, Granville DJ. 2005. Detection of apoptosis in cardio- vascular diseases. Methods Mol Med, 112:227-89.
39. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem, 67:425-79.
40. Hoeller D, Hecker CM, Dikic I. 2006. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer, 6:776-88.
41. Hoessel R, Leclerc S, Endicott JA, et al. 1999. Indirubin, the active con- stituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol, 1:60-7.
42. Hyatt JL, Moak T, Hatfield MJ, et al. 2007. Selective inhibition of carboxylesterases by isatins, indole, 2, 3-diones. J Med Chem, 50:1976-85.
43. Ignarro LG. 2002. Nitric oxide as a unique signalling molecule in the vascu- lar system: a hystorical overview. J Physiol Pharmacol, 53:503-14.
44. Ignarro LG, Cirino G, Casini A, et al. 1999. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovase Pharma- col, 34:879-86.
45. Igosheva N, Loiz C, O'Conner E, et al. 2005. Isatin, an endogenous mono- amine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells. Neurochem Int, 47:216-24.
46. Igosheva N, Matta S, Glover V. 2004. Effect of acute stress and gender on isatin in rat tissues and serum. Physiol Behav, 80:665-8.
47. Imahori K, Uchida T. 1997. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem, 121:179-88.
48. Iyer RA, Hanna PE. 1995. N-(carbobenzyloxy)isatin: a slow binding α-keto lactam inhibitor of α-chymotrypsin. Bioorg Med Chem Let, 5:89-92.
49. Ivanov YD, Panova NG, Gnedenko OV, et al. 2002. Study of the tissue and subcellular distribution of isatin-binding proteins with optical biosensor. Vopr Med Khim (Moscow), 48:73-83.
50. Ishitani R, Tajima H, Takata H, et al. 2003. Proapoptotic protein glyc- eraldehyde-3-phosphate dehydrogenase: a possible site of action of antiapoptotic drugs. Progr. Neuropsychopharmacol. Biol Psychiatry, 27:291-301.
51. Jellinger KA. 2006. Challenges in neuronal apoptosis. Curr Alzheimer Res, 3:377-91.
52. Jiang YH, Beaudet AL. 2004. Human disorders of ubiquitination and pro- teasomal degradation. Curr Opin Pediatr, 16:419-26.
53. Jin Z, El-Deiry WS. 2005. Overview of cell death signaling pathways. Cancer Biol Ther, 4:139-63.
54. Keefer LK. 2003. Progress toward clinical application of the nitric oxide-releasing diazoniumdiolates. Annu Rev Pharmacol Toxicol, 43:585-607.
55. Kovács J, Löw P, Pacz A, et al. 2003. Phosphoenolpyruvate-dependent tubulin-pyruvate kinase interaction at different organizational levels. J Biol Chem, 278:7126-30.
56. Kragten E, Lalande I, Zimmerman K, et al. 1998. Glyceradehyde- 3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R (-)-deprenyl. J Biol Chem, 273:5821-8.
57. Kuranada E, Miura M. 2007. Nonapoptotic functions of caspases: caspases as regulatory molecules for immunity and cell-fate determination. Trends Cell Biol, 17:135-44.
58. Leclerc S, Garnier M, Hoessel R, et al. 2001. Indirubins inhibit glycogen synthase kinase-3b and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's Disease. J Biol Chem, 276:251-60.
59. Lee D, Long SA, Murray JH, et al. 2001. Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem, 44:2015-26.
60. Levinson W, Faras A, Woodson B, et al. 1973. Inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus by thiosemicarbazones and several cations. Proc Nat Acad Sci USA, 70:164-8.
61. Lin SS, Chang SC, Wang YH, et al. 2000. Specific interaction between the hepatitis delta virus RNA and glyceraldehydes 3-phosphate dehydrogenase: an enhancement on ribozyme catalysis. Virology, 271:46-57.
62. Lohr JW, Willsky GR, Acara MA. 1998. Renal drug methabolism. Phar- macol Rev, 50:107-41.
63. Lonardo G, Cerbai E, Casini S, et al A. 2004. Atrial natriuretic peptide modulates the hyperpolarization-activated current (I(f)) in human atrial myocytes. Cardiovasc Res, 63:528-36.
64. Lucas FR, Goold RG, Gordon-Weeks PR, et al. 1998. Inhibition of GSK 3beta leading to the loss of phosphorylated MAP 1B is an early event in axonal remodelling induced by WNT- 7a or lithium. J Cell Sci, 111:1351-61.
65. Luscher TF. 1992. Endogenous and exogenous nitrates and their role in myocardial ischaemia. Br J Clin Pharmacol, 34 (Suppl 1):29S-35S.
66. Maggirwar SB, Tong N, Ramirez S, et al. 1999. HIV-1 Tat-mediated activation of glycogen synthase kinase 3beta contributes to Tat-mediated neurotoxicity. J Neurochem, 73:578-86.
67. Mak N-K, Leung C-Y, Wei X-Y, et al. 2004. Inhibition of RANTES expres- sion by indirubin in influenza virus-infected human bronchial epithelial cells. Biochem Pharmacol, 67:167-74.
68. Manabe S, Gao Q, Yuan J, et al. 1997. Determination of isatin in urine and plasma by highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl, 691:197-202.
69. Mandelkow E-M, Mandelkow E. 1998. Tau in Alzheimer's disease. Trends Cell Biol, 8:425-7.
70. Matheus ME, de Almeida Violante F, Garden SJ, et al. 2007. Isatins inhibit cyclooxygenase-2 and inducible nitric oxide synthase in a mouse macrophage cell line. Eur J Pharmacol, 556:200-6.
71. Mattson MP. 2006. Neuronal life - and death signaling, apoprosis and neurodegenerative disorders. Antioxid Redox Signal, 8:1997-2006.
72. Maruyama W, Akao Y, Youdim MB, et al. 2001. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem, 78:727-35.
73. Mawatari K, Segawa M, Masatsuka R, et al. 2001. Fluorimetric determi- nation of isatin in human urine and serum by liquid chromatography postcolumnphotoirradiation. Analyst, 126:33-6.
74. Medvedev AE, Adamik A, Glover V, et al. 2001. Cyclic GMP excretion blocked by isatin administration under conditions of fluid overload. Biochem Pharmacol, 62:225-7.
75. Medvedev A, Buneeva O, Gnedenko O, et al. 2006. Isatin interaction with glyceraldehydes-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl. J Neural Transm, 71(Suppl):97-103.
76. Medvedev A, Byssygina O, Pyatakova N, et al. 2002. Effect of isatin on nitric oxide-stimulated soluble guanylate cyclase from human platelets. Biochem Pharmacol, 63:763-6.
77. Medvedev AE, Clow A, Sandler M, et al. 1996. Isatin - a link between natriuretic peptides and monoamines? Biochem. Pharmacol, 52:385-91.
78. 3H]isatin binding sites in rat brain. Brain Res, 1042:119-24.
79. Medvedev AE, Glover V. 2004. Tribulin and endogenous MAO-inhibitory regulation in vivo. Neurotoxicology, 25:185-92.
80. Medvedev A, Igosheva N, Crumeyrolle-Arias M, et al. 2005. Isatin: role in stress and anxiety. Stress, 8:175-83.
81. Medvedev A, Sandler M, Glover V. 1998. Interaction of isatin with type-A natriuretic peptide receptor: possible mechanism. Life Sci, 62:2391-8.
82. Mehta SL, Manhas N, Raghubiz R. 2007. Molecular targets in cerebral isch- emia for developing novel therapeutics. Brain Res Rev, 54:34-66.
83. Misono KS. 2002. Natriuretic peptide receptor: structure and signaling. Mol Cell Biochem, 230:49-60.
84. Morgan D. 1997. Cyclin-dependent kinases: engines, clocks and micropro- cessors. Annu Rev Cell Dev Biol, 13:261-91.
85. Nagy E, Rigby WF. 1995. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Ross-man fold). J Biol Chem, 270:2755-63.
86. Napoli C, Ignarro LJ. 2003. Nitric oxide - releasing drugs. Annu Rev Phar- macol Toxicol, 43:97-123.
87. Pandeya SN, Smitha S, Jyoti M, et al. 2005. Biological activities of isatin and its derivatives. Acta Pharm, 55:27-46.
88. Panova NG, Zemskova NA, Axenova LN, et al. 1997. Does isatin interact with rat brain monoamine oxidases in vivo? Neurosci Lett, 233:58-60.
89. Panova NG, Buneeva OA, Gnedenko OV, et al. 2002. Isatin-binding activity of monoamine oxidase and glyceraldehydes-3-phosphate dehydroge- nase. Infammopharmacology, 9:295.
90. Pataki I, Adamic A, Telegdy G. 2000. Isatin (Indol-2, 3-dione) inhibits natriuretic peptide-induced hyperthermia in rats. Peptides, 21:373-7.
91. Pauwels R. 2006. Aspects of successful drug discovery and development. Antiviral Res, 71:77-89.
92. Pirrung MC, Panasare SV, Sarma KD, et al. 2005. Combinatorial optimiza- tion of isatin-beta-thiosemicarbazones as anti-poxvirus agents. J Med Chem, 48:3045-50.
93. Potter DE, Russell KR, Manhiani M. 2004. Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility. J Pharmacol Exp Ther, 309:548-53.
94. Potter LR, Abbey-Hosch S, Dickey DM. 2006. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Rev, 27:47-72.
95. Reeve JL, Duffy AM, O'Brien T, et al. 2005. Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. J Cell Mol Med, 9:609-22.
96. Reinoso RF, Telfer BA, Rowland M. 1997. Tissue water content in rats measured by desiccation. J Pharmacol Toxicol Methods, 38:87-92.
97. Rose CD, Martin TM. 2005. Caspase recruitment domain 15 mutations and rheumatic diseases. Curr Opin Rheumatol, 17:579-85.
98. Rowell EA, Wells AD. 2006. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. Crit Rev Immunol, 26:189-212.
99. Sandler M, Przyborowska A, Halket J, et al. 1991. Urinary but not brain isatin levels are reduced in germ-free rats. J Neurochem, 57:1074-5.
100. Senderowicz AM. 2003. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther, 2:S84-95.
101. Shimizu T, Uehara T, Nomura Y. 2004. Possible involvement of pyruvate kinase in acquisition of tolerance to hypoxic stress in glial cells. J Neurochem, 91:167-75.
102. Shuttleworth SJ, Nasturica D, Gervais CM, et al. 2000. Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Let, 10:2501-4.
103. Siegel RM. 2006. Caspases at the crossroads of immune-cell life and death. Natl Rev Immunol, 6:308-17.
104. Silberbach M, Roberts CT, Jr. 2001. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal, 13:221-31.
105. Sriram D, Bal TR, Yogeeswari P. 2004. Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeuticproperties. Bioorg Med Chem, 12:5865-73.
106. Sriram D, Bal TR, Yogeeswari Pl. 2005. Aminopyrimidinimino isatin analogues: Design of novel nonnucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. J Pharm Pharmaceut Sci, 8:565-77.
107. Stoneman VEA, Bennett M R. 2004. Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci, 107:343-54.
108. Summers SA, Kao AW, Kohn AD, et al. 1999. The role of glycogen syn- thase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem, 274:17934-40.
109. Tatton W, Chalmers-Redman R, Tatton N. 2003. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm, 110:509-15.
110. Telegdy G, Adamic A, Glover V. 2000. The action of isatin (2,3- indoldione) an endogenous indole on brain natriuretic peptide-induced facilitation of memory in passive-avoidance learning in rats. Brain Res, 874:194-9.
111. Testa V, Riccioni R. 2007. Deregulatioin of apoptosis in acute myeloid leukemia. Haematologica, 92:81-94.
112. Timmer JC, Salversen GS. 2007. Caspase substrates. Cell Death Differ, 14:66-72.
113. Tozawa Y, Ueki A, Manabe S, et al. 1998. Stress-induced increase in urinary isatin excretionin rats: Reversal by both dexamethasone and alpha-methyl-p-tyrosine. Biochem Pharmacol, 56:1041-6.
114. Trachte G. 2005. Neuronal regulation and function of natriuretic peptide receptor C. Peptides, 26:1060-7.
115. Troy CM, Salvesen GS. 2002. Caspases on the brain. J. Newrosci. Res, 69:145-50.
116. Tsutsumi H, Tani K, Fujii H, et al. 1988. Expression of L- and M-type pyruvate kinase in human tissues. Genomics, 2:86-92.
117. Usami K, Kitahara K, Ishikura S, et al. 2001. Characterization of a major form of human isatin reductase and the reduced metabolite. Eur J Biochem, 268:5755-63.
118. Verma M, Pandeya SN, Singh KN, et al. 2004. Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm, 54:49-56.
119. Vermeulen K, Van Bockstaele DR, Beznerman ZN. 2005. Apoptosis: mechanisms and relevance in cancer. Ann Hematol, 84:627-39.
120. Vértessy BG, Bánkfalvi D, Kovács J, et al. 1999. Piruvate kinase as a microtubule destabilizing factor in vitro. Biochem Biophys Res Commu, 254:420-35.
121. Wanga QM, Chen SH. 2007. Human rhinovirus 3C protease as a potential target for the development of antiviral agents. Curr Protein Pept Sci, 8:19-27.
122. Watkins P, Clow A, Glover V, et al. 1990. Isatin, regional distribution in rat brain and tissues. Neurochem Int, 17:321-3.
123. Webber SE, Tikhe J, Wozland ST, et al. 1996. Design, synthesis and evalu- ation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem, 39:5072-82.
124. Wells AD. 2007. Cyclin-dependent kinases: molecular switches control- ling anergy and potential therapeutic targets for tolerance. Seminars in Immunology, 19:173-9.
125. Wiedemann K, Jahn H, Kellner M. 2000. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes, 108:5-13.
126. Yamada K, Noguchi T. 1999. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J, 337:1-11.
127. Yang XM, Downey JM, Cohen MV. 2006. Atrial natriuretic peptide admin- istered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol, 101:311-18.
128. Yi M-K, Schultz DE, Lemon SM. 2000. Functional significance of the interaction of hepatitis A virus RNAwith glyceraldehyde 3-phosphate dehydrogenase (GAPDH): Opposing effects of GAPDH and polypy- rimidine tract binding protein on internal ribosome entry site function. J Virol, 74:6459-68.
129. Yost C, Torres M, Miller J R, et al. 1996. The axis-inducing activity, stabil- ity and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev, 10:1443-54.
130. Yuan J, Yankner BA. 2000. Apoptosis in the nervous system. Nature, 407:802-9.
131. Yury EC, Kabouridis PS, Abba A, et al. 2003. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum, 48:1343-54.